Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been given an average recommendation of “Buy” by the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $89.90.

Several brokerages recently commented on JANX. HC Wainwright boosted their target price on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. Leerink Partners boosted their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. Scotiabank upped their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a report on Wednesday, December 4th. Finally, William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th.

Insider Activity at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. This represents a 13.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of Janux Therapeutics stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $50.02, for a total value of $92,186.86. Following the transaction, the insider now directly owns 6,371 shares in the company, valued at approximately $318,677.42. This trade represents a 22.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 110,177 shares of company stock worth $6,162,207. 29.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Plato Investment Management Ltd increased its stake in shares of Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after acquiring an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares during the last quarter. Amalgamated Bank raised its stake in shares of Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares in the last quarter. Virtu Financial LLC lifted its holdings in shares of Janux Therapeutics by 48.0% during the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after buying an additional 2,419 shares during the last quarter. Finally, Zacks Investment Management grew its stake in shares of Janux Therapeutics by 8.7% in the 3rd quarter. Zacks Investment Management now owns 42,133 shares of the company’s stock valued at $1,914,000 after buying an additional 3,360 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $45.35 on Wednesday. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -38.76 and a beta of 3.23. Janux Therapeutics has a 1 year low of $7.79 and a 1 year high of $71.71. The business has a fifty day moving average of $53.85 and a 200-day moving average of $48.37.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics’s revenue for the quarter was down 82.6% on a year-over-year basis. On average, equities research analysts predict that Janux Therapeutics will post -1.35 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.